You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股普遍捱沽 信達、翰森及百濟神州跌6%-7%
恆指承過去三連跌勢,今早最多再跌190點或1.1%至16,455獲承接,掉頭曾重越10天線(16,705),最多倒升99點高見16,745,現報16,675,升29點或0.2%,總成交額372億元。 醫藥股普遍捱沽,藍籌翰森製藥(03692.HK)四連跌兼失守10天、50天及20天線,最低見13.6元(暫守250天線13.5元),現報13.82元,跌7.4%。百濟神州(06160.HK)跌穿20天及10天線,最低見99.45元,現報100.1元,下挫7.3%。信達生物(01801.HK)最低見38.55元,現報39元,下挫6.3%。 藍籌藥明生物(02269.HK)、騰盛博藥-B(02137.HK)、來凱醫藥-B(02105.HK)、康諾亞-B(02162.HK)、科倫博泰生物-B(06990.HK)、君實(01877.HK)、康寧傑瑞製藥-B(09966.HK)、諾誠健華(09969.HK)、康方生物(09926.HK)及金斯瑞生物(01548.HK)跌逾2%-3.5%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account